Research Corporation Technologies, Inc. (RCT), of Tucson, has partnered with Isogenica, of Cambridge, U.K., to access Isogenica’s CIS display platform for the screening of proprietary libraries of a new antigen-binding protein scaffold.

The RCT libraries are part of a biologics discovery platform to identify engineered antibody fragments called ABDURINS™ for development into therapeutic agents.  ABDURINS™ retain the desired long half-life of an antibody’s CH2 domain and are engineered for enhanced stability, epitope binding and other properties. To facilitate screening of the novel ABDURIN™ libraries, RCT has partnered with Isogenica to provide interested parties access to their proprietary, high throughput display and screening platform called CIS display. CIS display can screen significantly larger libraries and isolate and optimize lead binders in a fraction of the time it takes using phage display.  In addition to CIS display, Isogenica will support RCT through deep sequencing and related bioinformatics tools that can inform the optimisation of the selected ABDURINS™.

“Isogenica’s CIS display offers a significant advantage over other screening systems by allowing for primary screening and binder optimization in one system.  The pairing of CIS display with our ABDURIN™ platform will be an attractive offering to potential partners,” stated Dr. Kurt Gehlsen, Vice President and CSO of RCT.

Dr. Kevin Matthews, CEO of Isogenica commented, “Our agreement with RCT underlines the value that CIS display brings to companies that are pioneering new antibody scaffolds for the development of better medicines.  We look forward to supporting the deployment of RCT’s ABDURIN™ library and working with their biopharma collaborators to find new therapeutic candidates.”

Notes to Editors

About Isogenica

Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display.  Founded in 2000, Isogenica has developed a unique capability in the field of protein engineering.  Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.

For further information contact:

Kevin Matthews
CEO, Isogenica
Tel: +44 (0)1799 533682
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

About Research Corporation Technologies (RCT)

RCT is a Tucson, Arizona-based technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT’s ABDURIN ™ platform has been developed under collaboration with Dr. Dimitri Dimitrov’s Protein Interactions Group of the National Cancer Institute at the National Institutes of Health. To learn more, see

For RCT communications contact:
Rebecca Buescher
Tel:  1-520-748-4411
E: This email address is being protected from spambots. You need JavaScript enabled to view it.


PEGS Boston 2017

Boston, USA | 1st - 5th May 2016
Isogenica is pleased to be attending and presenting at this event and looks forward to meeting you

Read More

10th Annual Proteins & Antibodies Congress 2017

London, UK | 24th-25th April 2017
Isogenica is pleased to be attending and speaking at this event and looks forward to meeting you

Read More


Isogenica announces new discovery program with Molecular Templates

Cambridge, UK | 16th March 2016.


Isogenica and Molecular Templates of Georgetown, TX, have initiated a research program whereby Isogenica will use its...

Read More

New Chief Scientific Officer

Cambridge, UK | 1st January 2016.


Isogenica is delighted to announce the strengthening of its management team with the appointment of Dr Guy Hermans as Chief Scientific Officer.

Read More